Kaito Nihira
Tohoku University
5 Papers
Kaito Nihira is an academic researcher from Tohoku University. The author has contributed to research in topics: Immunology & Autophagy. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
An inhibition of p62/SQSTM1 caused autophagic cell death of several human carcinoma cells
TL;DR: Results of the present study revealed that an inhibition of p62 resulted in the formation of mis‐regulated autophagosomes with multilayer membranes and an autophagic cell death, and p62 can therefore be an attractive target for the development of anti‐neoplastic agents.
64
An activation of LC3A‐mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma
Kaito Nihira,Yasuhiro Miki,Shinya Iida,Sodai Narumi,Katsuhiko Ono,Erina Iwabuchi,Kazue Ise,Kazushige Mori,Mikiyoshi Saito,Masahito Ebina,Ikuro Sato,Makoto Maemondo,Hisafumi Yamada-Okabe,Takashi Kondo,Hironobu Sasano +14 more
TL;DR: It is demonstrated thatLC3A‐mediated autophagy in carcinoma cells was involved in the development of resistance to EGFR‐TKIs, and that LC3A could serve as a promising therapeutic target for overcoming resistance toEGFR‐ TKIs and a novel predictor of response to EG FR‐TkIs in lung adenocarcinoma patients.
47
A novel mouse model of cutaneous T‐cell lymphoma revealed the combined effect of mogamulizumab with psoralen and ultraviolet a therapy
TL;DR: Combination therapy of PUVA and mogamulizumab showed greater antitumor activity than either monotherapy with statistical significance, and in the histological analysis of the tumor tissue, PUVA accelerated tumor necrosis and then induced the infiltration inflammatory cells in the necrotic area, suggesting that these cells served as effector cells for mogamumab.
4
KK2845, a PBD dimer-containing antibody-drug conjugate targeting TIM-3-expressing AML.
Haruka Kinosada,Shin-Ichiro Takayanagi,Toshihiko Ishii,Toru Amano,Kaito Nihira,Shohei Kanie,Maiko Adachi,Harunobu Tahara,Teppei Sakoda,Yoshikane Kikushige,Koichi Akashi,Hidetaka Satou +11 more
[Non-clinical safety evaluations of next-generation therapeutic antibodies].
TL;DR: In this paper , the safety evaluation of bispecific antibodies and antibody-drug conjugates is discussed based on a literature review of these types of antibody drugs (approved or terminated due to toxicity).